Additionally, research has shown that T-DM1 is active in PIK3CA-mutant breast cancer cell lines and xenograft models, likely due to its unique mechanism of action, which involves the HER2-mediated delivery of a chemotherapeutic payload, independent of downstream HER2 signaling [62]. Here, ERBB2 is linked to breast carcinoma.